CYTOKINETICS INCORPOR

Cytokinetics Announces Pricing of $450 Million Convertible Senior Notes Offering

01 Jul 2022 02:35:20 By Nasdaq GlobeNewswire

Cytokinetics Announces Proposed Convertible Senior Notes Offering

29 Jun 2022 15:35:18 By Nasdaq GlobeNewswire

Cytokinetics Announces Date for FDA Advisory Committee Meeting to Review New Drug Application for Omecamtiv Mecarbil

24 Jun 2022 06:30:00 By Nasdaq GlobeNewswire

Cytokinetics Provides Regulatory Update for Omecamtiv Mecarbil

17 Jun 2022 06:30:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing COURAGE-ALS

16 Jun 2022 06:30:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Additional Data From REDWOOD-HCM Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions

13 Jun 2022 06:30:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Additional Results From REDWOOD-HCM to Be Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions

03 Jun 2022 15:00:41 By Nasdaq GlobeNewswire

Cytokinetics to Participate in Upcoming Investor Conferences

02 Jun 2022 15:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Jun 2022 15:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Data From REDWOOD-HCM OLE and GALACTIC-HF Presented as Late Breaking Science Presentations at the European Society of Cardiology Heart Failure 2022 Congress

23 May 2022 10:30:00 By Nasdaq GlobeNewswire